Bristol-Myers Squibb Company (BMY) Financial Statements

The financial quality of Bristol-Myers Squibb is bifurcated. On the positive side, the company demonstrates powerful cash generation and profitability metrics. A Free Cash Flow Yield of 10.7% is highly favourable, indicating strong conversion of earnings to cash for shareholders. The Return on Equity of 38.2% far exceeds the framework's 15-20% high-quality threshold, signalling efficient use of shareholder capital. The operating margin of 19.4% is robust. However, significant weaknesses are apparent. Revenue growth is anemic at 1.3% YoY, which fails the framework's check for consistent, double-digit growth and indicates a lack of durable growth trajectory. The balance sheet is a primary concern, with a Debt/Equity ratio of 2.44, which is high and exceeds the favourable threshold of low/zero debt (Debt/EBITDA < 1.0x). This leverage introduces financial risk. While the 4.2% dividend yield is attractive, it must be viewed in the context of the substantial debt burden. Overall, the company scores strongly on profitability and cash flow but weakly on growth and financial strength, resulting in an adequate but not high-quality profile per the framework's scoring system. Analysis based on data as of 2024-05-15.